Glucosamine and Its Surprising Link to Dementia Risk
A new study has generated considerable attention: Glucosamine, one of the most popular dietary supplements, may increase the risk of dementia in certain groups of people. Published in June 2026 in the journal Nature Metabolism, this research offers compelling insights into a potential connection between Glucosamine consumption and cognitive decline.
Examining the Study Findings
The researchers analyzed data from approximately 24,000 Alzheimer’s patients and 42,000 individuals with mild cognitive impairment. The findings revealed that among individuals with existing cognitive limitations, taking Glucosamine was associated with an elevated dementia risk of 25% over a five-year period. This alarming statistic raises questions about the safety of this widely used supplement.
However, the authors were careful to note that the data does not establish a causal relationship. It remains unclear whether the supplement directly contributes to cognitive decline or if other confounding factors are at play. Nonetheless, the results serve as a warning, especially for those already at risk of cognitive impairment.
This Market Boom Faces Safety Questions
The discussion occurs within a rapidly growing market. In 2025, the German dietary supplement market reached an impressive volume of around 4.3 billion euros, with approximately 415 million packages sold. This is a notable increase from 2022, which saw only 241 million packages sold.
Vitamins and minerals make up the largest share of the market at 48%. Magnesium, in particular, leads the way with around 75 million units sold. Most sales occur through drugstores (45%), with online sales accounting for 22.5% of the market.
Another notable trend is the rise of self-optimizing products, such as creatine. In the U.S., creatine sales skyrocketed by 60%. The sector exhibits a strong dependency on Asia, with an astonishing 84% of global creatine production currently coming from China.
Medications Under Scrutiny
It’s not just dietary supplements that are under the microscope. Analyses from June 2026 identified nine categories of medications associated with increased dementia risk. Of particular concern are anticholinergics like diphenhydramine or oxybutynin, which demonstrate a staggering 54% rise in risk. Proton pump inhibitors used for heartburn also pose a 44% increased risk of dementia.
Healthcare experts emphasize the importance of using guidelines such as the PRISCUS or FORTA lists for older patients, particularly as many commonly prescribed medications can unexpectedly impact cognitive health.
Understanding the Bigger Picture
The research surrounding brain aging is expanding. Two studies from June 2026 in Nature Communications and Nature Medicine follow the exposome approach, which considers the totality of environmental and lifestyle factors affecting health.
The studies draw upon extensive datasets, including the UK Biobank. Beyond cardiovascular diseases, smoking, and alcohol consumption, factors like air pollution, climate, and access to healthcare also impact brain structure.
Another study involving 18,700 participants from 34 countries found that socioeconomic inequality can act as an independent factor accelerating brain aging. This complexity underscores the necessity of a more holistic approach to dementia prevention that goes beyond managing supplements and medications.
In summary, the findings surrounding glucosamine should not be taken lightly. As research continues to evolve, it’s crucial for individuals to remain informed about the potential risks associated with popular dietary supplements and medications, especially as it pertains to cognitive health.
